Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Kim, Richard ^a   Schell, Michael J ^a   Teer, Jamie K ^a   Greenawalt, Danielle M ^b,d   Yang, Mingli ^c   Yeatman, Timothy J ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Gibbs Cancer Center   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; B RAF KINASE; K RAS PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; PROTEIN P53; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; DNA; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P21; RAS PROTEIN;

ADAMTS20 GENE; ADULT; AGED; APC GENE; ARTICLE; BRAF GENE; CARCINOGENESIS; CONTROLLED STUDY; CSMD3 GENE; DISTANT METASTASIS; FBXW7 GENE; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENE TARGETING; GENETIC CONSERVATION; GENOMICS; HSP90AB1 GENE; HUMAN; HUMAN TISSUE; JAK1 GENE; LUNG METASTASIS; LYMPH NODE METASTASIS; MACF1 GENE; MAJOR CLINICAL STUDY; MALE; MCF1 GENE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; OVARY METASTASIS; PIK3CA GENE; PREX1 GENE; PTPN13 GENE; PTPRC GENE; PTPRD GENE; RASA1 GENE; SMAD2 GENE; SMAD3 GENE; SMAD4 GENE; SOMATIC MUTATION; SYNE1 GENE; TP53 GENE; TTN GENE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; WNT2 GENE; ZNF217 GENE; ZNF831 GENE; COLORECTAL NEOPLASMS; DNA SEQUENCE; GENE EXPRESSION REGULATION; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; METASTASIS; MOLECULAR EVOLUTION; MUTATION; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA, NEOPLASM; EVOLUTION, MOLECULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 84929359174     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126670     Document Type: Article

References (29)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. Epub 2012/01/13. doi: 10.3322/caac.20138 PMID: 22237781.
2. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487 (7407):330-7. Epub 2012/07/20. doi: 10.1038/nature11252 PMID: 22810696; PubMed Central PMCID: PMC3401966.
3. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481(7381):306-13. doi: 10.1038/nature10762 PMID: 22258609; PubMed Central PMCID: PMC3367003.
4. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331(6024):1559-64. doi: 10.1126/science.1203543 PMID: 21436443.
5. Klein CA. Parallel progression of primary tumours and metastases. Nature reviews Cancer. 2009; 9(4):302-12. Epub 2009/03/25. doi: 10.1038/nrc2627 PMID: 19308069.
6. Lee SY, Haq F, Kim D, Jun C, Jo HJ, Ahn SM, et al. Comparative genomic analysis of primary and synchronous metastatic colorectal cancers. Plos One. 2014; 9(3):e90459. doi: 10.1371/journal.pone.0090459 PMID: 24599305; PubMed Central PMCID: PMC3944022.
7. Suzuki M, Tarin D. Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Molecular oncology. 2007; 1(2):172-80. Epub 2007/09/01. doi: 10.1016/j.molonc.2007.03.005 PMID: 19383293.
8. Urquidi V, Sloan D, Kawai K, Agarwal D, Woodman AC, Tarin D, et al. Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis. Clin Cancer Res. 2002; 8(1):61-74. Epub 2002/01/22. PMID: 11801541.
9. Montel V, Mose ES, Tarin D. Tumor-stromal interactions reciprocally modulate gene expression patterns during carcinogenesis and metastasis. Int J Cancer. 2006; 119(2):251-63. Epub 2006/02/17. doi: 10.1002/ijc.21757 PMID: 16482564.
10. Fenstermacher DA, Wenham RM, Rollison DE, Dalton WS. Implementing personalized medicine in a cancer center. Cancer journal. 2011; 17(6):528-36. doi: 10.1097/PPO.0b013e318238216e PMID: 22157297; PubMed Central PMCID: PMC3240816.
11. Yeatman TJ, Mule J, Dalton WS, Sullivan D. On the eve of personalized medicine in oncology. Cancer Res. 2008; 68(18):7250-2. Epub 2008/09/17. doi: 10.1158/0008-5472.CAN-08-1374 PMID: 18794109; PubMed Central PMCID: PMC2650840.
12. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, et al. Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15 (24):7642-51. doi: 10.1158/1078-0432.CCR-09-1431 PMID: 19996206; PubMed Central PMCID: PMC2920750.
13. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature genetics. 2011; 43 (5):491-8. doi: 10.1038/ng.806 PMID: 21478889; PubMed Central PMCID: PMC3083463.
14. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic acids research. 2010; 38(16):e164. doi: 10.1093/nar/gkq603 PMID: 20601685; PubMed Central PMCID: PMC2938201.
15. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25(16):2078-9. doi: 10.1093/bioinformatics/btp352 PMID: 19505943; PubMed Central PMCID: PMC2723002.
16. Fuentes Fajardo KV, Adams D, Program NCS, Mason CE, Sincan M, Tifft C, et al. Detecting false-positive signals in exome sequencing. Human mutation. 2012; 33(4):609-13. doi: 10.1002/humu.22033 PMID: 22294350; PubMed Central PMCID: PMC3302978.
17. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-8. doi: 10.1038/nature12213 PMID: 23770567; PubMed Central PMCID: PMC3919509.
18. Bissig H, Richter J, Desper R, Meier V, Schraml P, Schaffer AA, et al. Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization. The American journal of pathology. 1999; 155(1):267-74. Epub 1999/07/08. doi: 10.1016/S0002-9440(10)65120-6 PMID: 10393858; PubMed Central PMCID: PMC1866676.
19. Kuukasjarvi T, Karhu R, Tanner M, Kahkonen M, Schaffer A, Nupponen N, et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res. 1997; 57(8):1597-604. Epub 1997/04/15. PMID: 9108466.
20. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23-8. Epub 1976/10/01. PMID: 959840.
21. Gartner JJ, Davis S, Wei XM, Lin JC, Trivedi NS, Teer JK, et al. Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. Bmc Genomics. 2012; 13. Artn 505 doi: 10.1186/1471-2164-13-505 PMID: ISI:000311358600001.
22. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012; 30(24):2956-62. Epub 2012/06/06. doi: 10.1200/JCO.2011.38.2994 PMID: 22665543; PubMed Central PMCID: PMC3417049.
23. Vignot S, Frampton GM, Soria JC, Yelensky R, Commo F, Brambilla C, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol. 2013; 31(17):2167-72. Epub 2013/05/01. doi: 10.1200/JCO.2012.47.7737 PMID: 23630207.
24. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat. 2003; 21(3):271-6. Epub 2003/03/06. doi: 10.1002/humu.10175 PMID: 12619112.
25. Forslund A, Lonnroth C, Andersson M, Brevinge H, Lundholm K. Mutations and allelic loss of p53 in primary tumor DNA from potentially cured patients with colorectal carcinoma. J Clin Oncol. 2001; 19 (11):2829-36. Epub 2001/06/02. PMID: 11387354.
26. Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends in cell biology. 2010; 20(7):427-34. doi: 10.1016/j.tcb.2010.03.004 PMID: 20399660; PubMed Central PMCID: PMC2921989.
27. Khan ZA, Jonas SK, Le-Marer N, Patel H, Wharton RQ, Tarragona A, et al. P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients. Clin Cancer Res. 2000; 6(9):3499-504. Epub 2000/09/22. PMID: 10999735.
28. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319(9):525-32. Epub 1988/09/01. doi: 10.1056/NEJM198809013190901 PMID: 2841597.
29. Julien SG, Dube N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer. 2011; 11(1):35-49. Epub 2010/12/24. doi: 10.1038/nrc2980 PMID: 21179176.